Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 5/20 | 0.51 |
| ▸ | HCRTR2 | O43614 | 5/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | ACACB | O00763 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL385013 | 1.00 | HCRTR1 (0.51) | HCRTR1HCRTR2SMN1; SMN2HPGDKDM4E | |
| SCHEMBL1066934 | 0.96 | HCRTR1 (0.49) | HCRTR1HCRTR2SMN1; SMN2HPGDKDM4E | |
| SCHEMBL16433613 | 0.93 | HCRTR1 (0.49) | HCRTR1HCRTR2SMN1; SMN2HPGDKDM4E | |
| SCHEMBL16433636 | 0.90 | HCRTR1 (0.47) | HCRTR1HCRTR2SMN1; SMN2HPGDKDM4E | |
| SCHEMBL12932352 | 0.88 | HCRTR1 (0.55) | HCRTR1HCRTR2SMN1; SMN2HPGDKDM4E | |
| SCHEMBL10107157 | 0.84 | HCRTR1 (0.46) | HCRTR1HCRTR2SMN1; SMN2HPGDKDM4E | |
| SCHEMBL382980 | 0.84 | HCRTR1 (0.46) | HCRTR1HCRTR2SMN1; SMN2HPGDKDM4E | |
| SCHEMBL12371239 | 0.84 | KDM4E (0.49) | HCRTR1HCRTR2SMN1; SMN2HPGDKDM4E | |
| SCHEMBL10107166 | 0.84 | HCRTR1 (0.53) | HCRTR1HCRTR2SMN1; SMN2HPGDKDM4E | |
| SCHEMBL12386009 | 0.83 | CYP3A4 (0.39) | HCRTR1HCRTR2KDM4EACACBGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101768-B2 | Cyclic amine compound and pest control agent | NIPPON SODA CO., LTD. (JP) | 2012-01-24 | — | — | US | disclosed |
| US-7994094-B2 | N-pyridylpiperidine compound, method for producing the same, and pest control agent | OTSUKA AGRITECHNO CO., LTD. (JP) | 2011-08-09 | — | — | US | disclosed |
| US-20100137582-A1 | N-PYRIDYLPIPERIDINE COMPOUND, METHOD FOR PRODUCING THE SAME, AND PEST CONTROL AGENT | OTSUKA CHEMICAL CO., LTD. (JP) | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137582-A1 | N-PYRIDYLPIPERIDINE COMPOUND, METHOD FOR PRODUCING THE SAME, AND PEST CONTROL AGENT | HRH4, NOX4, PRDX4 | HCRTR1 329/4885HCRTR2 860/4885SMN1; SMN2 2257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.